Table 2.
SBRT for prostate cancer with at least 30-month follow-up
| Study | Phase | Patients (n) | Risk group | Median FU (months) | Total dose (Gy) | Total fractions | Gy per fraction | BED (Gy) at a/b of 1.5 (for TC) | BED (Gy) at a/b of 3.0 (for LT) | Actuarial FFBFa | RTOG/CTCAE late toxicity grade ≥2 (%)
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GU | GI | |||||||||||
| Gantry | ||||||||||||
| Madsen et al8 | I/II | 40 | L | 41 | 33.5 | 5 | 6.7 | 156 | 82 | 2 years: 90% | 20 | 7.5 |
| Loblaw et al9 | I/II | 84 | L | 55 | 35 | 5 | 7 | 170 | 89 | 5 years: 98% | 5 | 8 |
| Mantz10 | II | 102 | L | 60 | 40 | 5 | 8 | 221 | 115 | 5 years: 100% | NR | NR |
| Robotic arm | ||||||||||||
| Friedland et al11 | NA | 112 | L, I, H | 48 | 35 | 5 | 7 | 170 | 89 | 3 years: 97% | NR | NR |
| Katz et al12,13 | I/II | 50 | L, I, H | 40 | 35 | 5 | 7 | 170 | 89 | 4 years: 98.5%, 93%, 75%c | 7.8 | 4.2 |
| 254 | 36.3 | 5 | 7.3 | 182 | 95 | |||||||
| Kang et al14 | NA | 5 | L, I, H | 40 | 32 | 4 | 8 | 179 | 93 | 5 years: 100%, 100%, 90.8%c | 6.8 | 11 |
| 28 | 34 | 4 | 8.5 | 201 | 105 | |||||||
| 11 | 36 | 4 | 9 | 225 | 117 | |||||||
| McBride et al15 | I | 10 | L | 45 | 37.5 | 5 | 7.5 | 195 | 101 | 3 years: 98% | 19.2 | 12 |
| 34 | 36.3 | 5 | 7.3 | 182 | 95 | |||||||
| 1 | NA | |||||||||||
| King et al16 | II | 16 | L | 32 | 36.3 | 5 | 7.3 | 182 | 95 | 4 years: 94% | 8.7 | 2 |
| 41 | 36.3 | 5 | 7.3 | 182 | 95 | |||||||
| King et al17,18,b | II | 1,100 | L, I, H | 36 | 35–40 | 4–5 | NA | NA | NA | 5 years: 93% (95%, 84%, 81%)c | NR | NR |
| Bolzicco et al19 | II | 100 | L, I, H | 36 | 35 | 5 | 7 | 170 | 89 | 3 years: 94.4% | 4 | 1 |
| Katz and Kang20,21,b | Ret | 154 | L, I | 72 | 35 | 5 | 7 | 170 | 89 | 7 years: 93.7% (95.6%, 89.6%)c | NR | NR |
| 323 | 36.3 | 5 | 7.3 | 182 | 95 | |||||||
| Ret | 158 | L, I, H | 72 | 35 | 5 | 7 | 170 | 89 | 7 years: 95.8%, 89.3%, 68.5%c | 10.9 | 4.1 | |
| 357 | 36.3 | 5 | 7.3 | 182 | 95 | |||||||
| Fuller et al22 | II | 53 | L, I | 60 | 38 | 4 | 9.5 | 250 | 130 | 5 years: 100%, 92%c | 15 | 1 |
| Lee et al23 | Ret | 29 | L, I, H | 41 | 35–37.5 | 5 | NA | NA | NA | 4 years: 92.8% | 6 | 0 |
| Bernetich et al24 | Ret | 5 | L, I, H | 38 | 35 | 5 | 7 | 170 | 89 | 5 years: 92.7% (94.4%, 94.2%, 83.9%)c | 16 | 3 |
| 107 | 36.3 | 5 | 7.3 | 182 | 95 | |||||||
| 30 | 37.5 | 5 | 7.5 | 195 | 101 | |||||||
Notes:
Listed as overall FFBF or for low-, intermediate-, and high-risk groups;
at least some data published previously.
For actuarial FFBF, low, intermediate, and high risk group data shown as separate values if available. The α/β ratio provides an estimate of the radiosensitivity of cells.
Abbreviations: BED, biological equivalent dose; CTCAE, Common Terminology Criteria for Adverse Events; FFBF, freedom from biochemical failure; FU, follow-up; GI, gastrointestinal; GU, genitourinary; H, high; I, intermediate; L, low; LT, late toxicity; NA, not applicable; NR, not reported; Ret, retrospective; RTOG, Radiation Therapy Oncology Group; SBRT, stereotactic body radiation therapy; TC, tumor control.